- Home
- LGND vs ZLAB Comparison
LGND vs ZLAB Comparison
Compare LGND & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- ZLAB
- Stock Information
- Founded
- LGND 1987
- ZLAB 2013
- Country
- LGND United States
- ZLAB China
- Employees
- LGND 68
- ZLAB N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- LGND Health Care
- ZLAB Health Care
- Exchange
- LGND Nasdaq
- ZLAB Nasdaq
- Market Cap
- LGND 3.2B
- ZLAB 3.6B
- IPO Year
- LGND 1992
- ZLAB 2017
- Fundamental
- Price
- LGND $184.49
- ZLAB $33.69
- Analyst Decision
- LGND Strong Buy
- ZLAB Buy
- Analyst Count
- LGND 8
- ZLAB 6
- Target Price
- LGND $144.71
- ZLAB $57.22
- AVG Volume (30 Days)
- LGND 139.7K
- ZLAB 647.2K
- Earning Date
- LGND 08-05-2025
- ZLAB 11-11-2025
- Dividend Yield
- LGND N/A
- ZLAB N/A
- EPS Growth
- LGND N/A
- ZLAB N/A
- EPS
- LGND N/A
- ZLAB N/A
- Revenue
- LGND $181,488,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- LGND $18.41
- ZLAB $41.60
- Revenue Next Year
- LGND $18.87
- ZLAB $53.42
- P/E Ratio
- LGND N/A
- ZLAB N/A
- Revenue Growth
- LGND 53.40
- ZLAB 32.56
- 52 Week Low
- LGND $81.74
- ZLAB $23.70
- 52 Week High
- LGND $129.90
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- LGND 79.42
- ZLAB 51.53
- Support Level
- LGND $179.40
- ZLAB $32.87
- Resistance Level
- LGND $184.26
- ZLAB $34.72
- Average True Range (ATR)
- LGND 4.60
- ZLAB 0.88
- MACD
- LGND 0.44
- ZLAB 0.17
- Stochastic Oscillator
- LGND 100.00
- ZLAB 62.13
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.